Literature DB >> 29893006

Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Zhaleh Asadi Fakhr1, Valiollah Mehrzad2, Amin Izaditabar3, Mansoor Salehi1,3.   

Abstract

OBJECTIVE: To clear the role of peripheral blood as a substitution for bone marrow in myelodysplastic syndrome and to evaluate the concordance between peripheral blood and bone marrow using karyotype and fluorescence in situ hybridization (FISH) methods.
METHODS: We examined 35 bone marrow (BM) and peripheral blood (PB) samples from myelodysplastic syndrome (MDS) patient using karyotype and FISH. Karyotype method for BM and PB samples performed using the standard protocol with an exception for peripheral blood in which growth factor for cultivation was not used. FISH testing was performed using a panel of MDS-associated probes to detect 20q12, 20qter, 5q31, 5q33, 5p15 and chromosome 7 and 8 centromeres.
RESULTS: Our results showed karyotypes of BM and PB are concordant in 74% of cases, while about 53% of these concordances were achieved from cases with normal karyotypes. However, the results of BM FISH were completely concordant with PB FISH.
CONCLUSION: Although peripheral blood karyotype is not trustworthy for MDS diagnosis, examining peripheral blood, using the FISH method, could be useful for clinical monitoring.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone marrow; fluorescence in situ hybridization; karyotype; myelodysplastic syndrome; peripheral blood

Mesh:

Year:  2018        PMID: 29893006      PMCID: PMC6817227          DOI: 10.1002/jcla.22586

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  22 in total

1.  Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?

Authors:  Athena M Cherry; Marilyn L Slovak; Lynda J Campbell; Kathy Chun; Virginie Eclache; Detlef Haase; Claudia Haferlach; Barbara Hildebrandt; Anwar M Iqbal; Suresh C Jhanwar; Kazuma Ohyashiki; Francesc Sole; Peter Vandenberghe; Daniel L VanDyke; Yanming Zhang; Gordon W Dewald
Journal:  Leuk Res       Date:  2012-04-25       Impact factor: 3.156

2.  Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH.

Authors:  Rhett P Ketterling; William A Wyatt; Scott A VanWier; Mark Law; Janice M Hodnefield; Curtis A Hanson; Gordon W Dewald
Journal:  Leuk Res       Date:  2002-03       Impact factor: 3.156

Review 3.  Myelodysplastic syndromes.

Authors:  Lionel Adès; Raphael Itzykson; Pierre Fenaux
Journal:  Lancet       Date:  2014-03-21       Impact factor: 79.321

4.  Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients.

Authors:  P Bernasconi; P M Cavigliano; M Boni; S Calatroni; C Klersy; I Giardini; B Rocca; N Crosetto; M Caresana; M Lazzarino; C Bernasconi
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

5.  Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes.

Authors:  Katarzyna Skonieczka; Ewa Duszeńko; Elzbieta Wyrowińska; Olga Haus
Journal:  Pol Arch Med Wewn       Date:  2009-06

6.  Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.

Authors:  Matteo Giovanni Della Porta; Luca Malcovati; Emanuela Boveri; Erica Travaglino; Daniela Pietra; Cristiana Pascutto; Francesco Passamonti; Rosangela Invernizzi; Alessandro Castello; Umberto Magrini; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

7.  Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients.

Authors:  Maura Romeo; Maria de Lourdes Chauffaille; Maria Regina R Silva; Daniella M M Bahia; José Kerbauy
Journal:  Leuk Res       Date:  2002-11       Impact factor: 3.156

8.  Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Authors:  Zhaleh Asadi Fakhr; Valiollah Mehrzad; Amin Izaditabar; Mansoor Salehi
Journal:  J Clin Lab Anal       Date:  2018-06-11       Impact factor: 2.352

9.  Identifying the similarities and differences between single nucleotide polymorphism array (SNPa) analysis and karyotyping in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Thiago Rodrigo de Noronha; Sandra Serson Rohr; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2014-11-21

10.  Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes.

Authors:  Roman Martin; Pamela Acha; Christina Ganster; Laura Palomo; Sascha Dierks; Francisco Fuster-Tormo; Mar Mallo; Vera Ademà; Paula Gómez-Marzo; Nuri De Haro; Neus Solanes; Lurdes Zamora; Blanca Xicoy; Katayoon Shirneshan; Johanna Flach; Friederike Braulke; Julie Schanz; Arkadiusz Kominowski; Martin Stromburg; Alina Brockmann; Lorenz Trümper; Francesc Solé; Detlef Haase
Journal:  Am J Hematol       Date:  2018-04-10       Impact factor: 10.047

View more
  1 in total

1.  Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Authors:  Zhaleh Asadi Fakhr; Valiollah Mehrzad; Amin Izaditabar; Mansoor Salehi
Journal:  J Clin Lab Anal       Date:  2018-06-11       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.